tbuckley/cabot-search huggingface dataset:
Next-Generation Opioid Scripts—Postpancreatectomy ERAS
Authors: Melissa E. Hogg
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Retrospective pharmacogenetic study of psoriasis highlights the role of <i>KLK7</i> in tumour necrosis factor signalling
Authors: Haihan Zhang, Matthew T Patrick, Trilokraj Tejasvi, Mrinal K Sarkar, Rachael Wasikowski, Philip E Stuart, Qinmengge Li, Xianying Xing, John J Voorhees, Nicole L Ward, Kevin He, Xiang Zhou, Johann E Gudjonsson, Rajan P Nair, James T Elder, Lam C Tsoi
Journal: British Journal of Dermatology (2023)

Abstract Background Multiple treatment options are available for the management of psoriasis, but clinical response varies among individual patients and no biomarkers are available to facilitate treatment selection for improved patient outcomes. Objectives To utilize retrospective data to conduct a pharmacogenetic study to explore the potential genetic pathways associated with drug response in the treatment of psoriasis. Methods We conducted a retrospective pharmacogenetic study using self-evaluated treatment response from 1942 genotyped patients with psoriasis. We examined 6 502 658 genetic markers to model their associations with response to six treatment options using linear regression, adjusting for cohort variables and demographic features. We further utilized an integrative approach incorporating epigenomics, transcriptomics and a longitudinal clinical cohort to provide biological implications for the topmost signals associated with drug response. Results Two novel markers were revealed to be associated with treatment response: rs1991820 (P = 1.30 × 10–6) for anti-tumour necrosis factor (TNF) biologics; and rs62264137 (P = 2.94 × 10–6) for methotrexate, which was also associated with cutaneous mRNA expression levels of two known psoriasis-related genes KLK7 (P = 1.0 × 10–12) and CD200 (P = 5.4 × 10–6). We demonstrated that KLK7 expression was increased in the psoriatic epidermis, as shown by immunohistochemistry, as well as single-cell RNA sequencing, and its responsiveness to anti-TNF treatment was highlighted. By inhibiting the expression of KLK7, we further illustrated that keratinocytes have decreased proinflammatory responses to TNF. Conclusions Our study implicates the genetic regulation of cytokine responses in predicting clinical drug response and supports the association between pharmacogenetic loci and anti-TNF response, as shown here for KLK7.
Risankizumab versus apremilast in the era of skin clearance
Authors: Emma Veysey
Journal: British Journal of Dermatology (2023)

Journal Article Accepted manuscript Risankizumab vs. apremilast in the era of skin clearance Get access Emma Veysey Emma Veysey Dermatology Department, St Vincent’s Hospital, Melbourne, Australia Email:emma.veysey@svha.org.au Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad328, https://doi.org/10.1093/bjd/ljad328 Published: 06 September 2023 Article history Received: 16 August 2023 Revision received: 27 August 2023 Accepted: 04 September 2023 Published: 06 September 2023
Ambient-stable topical rapamycin cream is effective in treating angiofibromas in tuberous sclerosis complex
Authors: Chien-Hui Hong, Chih-Hung Lee
Journal: British Journal of Dermatology (2023)

Journal Article Ambient-stable topical rapamycin cream is effective in treating angiofibromas in tuberous sclerosis complex Get access Chien-Hui Hong, Chien-Hui Hong Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Software, Validation, Visualization, Writing - original draft Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, TaiwanDepartment of Dermatology, National Yang-Ming Chiao-Tung University College of Medicine, Taipei, Taiwan Search for other works by this author on: Oxford Academic Google Scholar Chih-Hung Lee Chih-Hung Lee Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDepartment of Dermatology, Chang Gung University College of Medicine, Taoyuan, TaiwanSchool of Medicine, National Sun Yat-Sen University, Kaohsiung, TaiwanInstitute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan Correspondence: Chih-Hung Lee. Email: dermlee@gmail.com https://orcid.org/0000-0001-9804-3874 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 189, Issue 5, November 2023, Pages 507–508, https://doi.org/10.1093/bjd/ljad334 Published: 06 September 2023 Article history Received: 28 August 2023 Accepted: 02 September 2023 Published: 06 September 2023 Corrected and typeset: 11 October 2023
Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study
Authors: Amani Meaidi, Annamaria Mascolo, Maurizio Sessa, Anne Pernille Toft-Petersen, Regitze Skals, Thomas Alexander Gerds, Charlotte Wessel Skovlund, Lina Steinrud Morch, Francesco Rossi, Annalisa Capuano, Oejvind Lidegaard, Christian Torp-Pedersen
Journal: BMJ (2023)

Abstract Objective To study the influence of concomitant use of hormonal contraception and non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of venous thromboembolism. Design Nationwide cohort study. Setting Denmark through national registries. Participants All 15-49 year old women living in Denmark between 1996 and 2017 with no medical history of any venous or arterial thrombotic event, cancer, thrombophilia, hysterectomy, bilateral oophorectomy, sterilisation, or infertility treatment (n=2 029 065). Main outcome measure A first time discharge diagnosis of lower limb deep venous thrombosis or pulmonary embolism. Results Among 2.0 million women followed for 21.0 million person years, 8710 venous thromboembolic events occurred. Compared with non-use of NSAIDs, use of NSAIDs was associated with an adjusted incidence rate ratio of venous thromboembolism of 7.2 (95% confidence interval 6.0 to 8.5) in women not using hormonal contraception, 11.0 (9.6 to 12.6) in women using high risk hormonal contraception, 7.9 (5.9 to 10.6) in those using medium risk hormonal contraception, and 4.5 (2.6 to 8.1) in users of low/no risk hormonal contraception. The corresponding numbers of extra venous thromboembolic events per 100 000 women over the first week of NSAID treatment compared with non-use of NSAIDs were 4 (3 to 5) in women not using hormonal contraception, 23 (19 to 27) in women using high risk hormonal contraception, 11 (7 to 15) in those using medium risk hormonal contraception, and 3 (0 to 5) in users of low/no risk hormonal contraception. Conclusions NSAID use was positively associated with the development of venous thromboembolism in women of reproductive age. The number of extra venous thromboembolic events with NSAID use compared with non-use was significantly larger with concomitant use of high/medium risk hormonal contraception compared with concomitant use of low/no risk hormonal contraception. Women needing both hormonal contraception and regular use of NSAIDs should be advised accordingly.
Correcting batch effects in large-scale multiomics studies using a reference-material-based ratio method
Authors: Ying Yu, Naixin Zhang, Yuanbang Mai, Luyao Ren, Qiaochu Chen, Zehui Cao, Qingwang Chen, Yaqing Liu, Wanwan Hou, Jingcheng Yang, Huixiao Hong, Joshua Xu, Weida Tong, Lianhua Dong, Leming Shi, Xiang Fang, Yuanting Zheng
Journal: Genome biology (2023)

Batch effects are notoriously common technical variations in multiomics data and may result in misleading outcomes if uncorrected or over-corrected. A plethora of batch-effect correction algorithms are proposed to facilitate data integration. However, their respective advantages and limitations are not adequately assessed in terms of omics types, the performance metrics, and the application scenarios.
Affirmative Action, Population Health, and the Importance of Opportunity and Hope
Authors: Atheendar S Venkataramani
Journal: New England Journal of Medicine (2023)

Interview with Atheendar Venkataramani on affirmative action and how hope and opportunity can affect health and well-being. (08:37)Download Policy discussions related to affirmative action have typically focused on its effects on education, employment, and earnings. But affirmative action may also play a role in shaping population health.
Reply to Li <i>et al</i>.
Authors: Lei Wang, Yang Cai, Johan Garssen, Paul A. J. Henricks, Gert Folkerts, Saskia Braber
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Reply to: Gut Microbiota Dysbiosis and Chronic Obstructive Pulmonary Disease: A Question of Chicken and Egg." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Gut Microbiota Dysbiosis and Chronic Obstructive Pulmonary Disease: A Question of Chicken and Egg
Authors: Naijian Li, Nian Wang, Pixin Ran
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Gut Microbiota Dysbiosis and Chronic Obstructive Pulmonary Disease: A Question of Chicken and Egg." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
The Lancet Commission on peaceful societies through health equity and gender equality
Authors: Valerie Percival, Oskar T Thoms, Ben Oppenheim, Dane Rowlands, Carolyn Chisadza, Sara Fewer, Gavin Yamey, Amy C Alexander, Chloe L Allaham, Sara Causevic, François Daudelin, Siri Gloppen, Debarati Guha-Sapir, Maseh Hadaf, Samuel Henderson, Steven J Hoffman, Ana Langer, Toni Joe Lebbos, Luiz Leomil, Minna Lyytikäinen, Anju Malhotra, Paul Mkandawire, Holly A Norris, Ole Petter Ottersen, Jason Phillips, Sigrún Rawet, Alexa Salikova, Idil Shekh Mohamed, Ghazal Zazai, Tarja Halonen, Catherine Kyobutungi, Zulfiqar A Bhutta, Peter Friberg
Journal: The Lancet (2023)
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023
Authors: Therese B. Bevers, Bethany L. Niell, Jennifer L. Baker, Debbie L. Bennett, Ermelinda Bonaccio, Melissa S. Camp, Sona Chikarmane, Emily F. Conant, Mohammad Eghtedari, Meghan R. Flanagan, Jeffrey Hawley, Mark Helvie, Linda Hodgkiss, Tamarya L. Hoyt, Jennifer Ivanovich, Maxine S. Jochelson, Swati Kulkarni, Rachael B. Lancaster, Caitlin Mauer, Jessica Maxwell, Bhavika K. Patel, Mark Pearlman, Liane Philpotts, Donna Plecha, Jennifer K. Plichta, Shadi Shakeri, Mary Lou Smith, Clarie L. Streibert, Roberta M. Strigel, Lusine Tumyan, Nicole S. Winkler, Dulcy E. Wolverton, Mary Anne Bergman, Rashmi Kumar, Katie Stehman
Journal: Journal of the National Comprehensive Cancer Network (2023)

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.
NCCN Policy Summit: Reducing the Cancer Burden Through Prevention and Early Detection
Authors: Lindsey Bandini, Alyssa Schatz, Victoria Hood, Nikia Clark, Michael J. Hall, Robert W. Carlson
Journal: Journal of the National Comprehensive Cancer Network (2023)

Cancer prevention, screening, and early detection play an integral role in cancer incidence and outcomes. It is estimated that 30% to 50% of cancers worldwide are preventable, and it is well established that early detection of many cancers is associated with improved treatment outcomes. A recent NCCN Policy Summit: Reducing the Cancer Burden Through Prevention and Early Detection brought together healthcare providers, payers, policymakers, patient advocates, industry representatives, and technology representatives to explore challenges, triumphs, and outstanding questions surrounding current practices. Keynotes were delivered by Dr. Lisa Richardson, Director of the Division of Cancer Prevention and Control within the CDC, and Dr. Danielle Carnival, White House Cancer Moonshot Coordinator. Dr. Richardson focused on the field of public health, translating its utility in preventing and diagnosing cancer in the United States, while Dr. Carnival discussed ambitious goals by the Cancer Moonshot in reducing the cancer burden. Panelists highlighted characteristics of high-impact prevention and early detection programs, including how genetic testing has impacted this space. Existing programs are often challenged due to limitations in data, as well as financial, structural, and social barriers to motivating individuals to act on recommendations. Despite these barriers, we can learn from highly successful programs and should apply proven attributes, such as community engagement, more broadly.
HLA‐E<sup>high</sup>/HLA‐G<sup>high</sup>/HLA‐II<sup>low</sup> Human iPSC‐Derived Cardiomyocytes Exhibit Low Immunogenicity for Heart Regeneration
Authors: Yi‐Hsien Fang, Saprina P. H. Wang, I‐Chuang Liao, Kuen‐Jer Tsai, Po‐Hsien Huang, Pei‐Jung Yang, Chia‐Jui Yen, Ping‐Yen Liu, Yan‐Shen Shan, Yen‐Wen Liu
Journal: Advanced Healthcare Materials (2023)

Although human pluripotent stem cells (hPSCs)-derived cardiomyocytes (hPSC-CMs) can remuscularize infarcted hearts and restore post-infarct cardiac function, post-transplant rejection resulting from human leukocyte antigen (HLA) mismatching is an enormous obstacle. It is crucial to identify hypoimmunogenic hPSCs for allogeneic cell therapy. This study is conducted to demonstrate the immune privilege of HLA-Ehigh /HLA-Ghigh /HLA-IIlow human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs). Ischemia-reperfusion surgery is done to create transmural myocardial infarction in rats. At post-infarct 4 days, hPSC-CMs (1.0×107 cells per kg), including human embryonic stem cell-derived cardiomyocytes (hESC-CMs), HLA-Elow/HLA-Glow/HLA-IIhigh hiPSC-CMs, and HLA-Ehigh /HLA-Ghigh /HLA-IIlow hiPSC-CMs, are injected into the infarcted myocardium. Under the treatment of very low dose cyclosporine A (CsA), only HLA-Ehigh /HLA-Ghigh /HLA-IIlow hiPSC-CMs survive in vivo and improved post-infarct cardiac function with infarct size reduction. HLA-Ehigh /HLA-Ghigh /HLA-IIlow hiPSC-CMs activate the SHP-1 signaling pathway of natural killer (NK) cells and cytotoxic T cells to evade attack by NK cells and cytotoxic T cells. Herein, it is demonstrated that using a clinically relevant CsA dose, HLA-Ehigh /HLA-Ghigh /HLA-IIlow hiPSC-CMs repair the infarcted myocardium and restore the post-infarct heart function. HLA-Ehigh /HLA-Ghigh /HLA-IIlow hiPSCs are less immunogenic and may serve as platforms for regeneration medicine.
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Authors: David S. Ettinger, Douglas E. Wood, James Stevenson, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes
Journal: Journal of the National Comprehensive Cancer Network (2023)

Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose. The term “malignant” is no longer used to classify mesotheliomas, because all mesotheliomas are now defined as malignant.
Principles of Surgical Management of Peritoneal Mesothelioma
Authors: Jessica A. Steadman, Travis E. Grotz
Journal: Journal of the National Comprehensive Cancer Network (2023)

Malignant peritoneal mesothelioma (MPeM) is a rare malignancy and represents 5% to 30% of malignant mesothelioma cases. The primary curative therapy for MPeM is radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with the strongest predictor of long-term survival being complete cytoreduction. There is a paucity of high-quality evidence available to guide management in MPeM; however, NCCN Guidelines for the management of MPeM were updated this year. In well-selected patients, 5-year overall survival exceeds 65%, but achieving optimal results requires careful preoperative evaluation and expert surgical management. Preoperative patient selection includes histology review and staging with cross-sectional imaging. Ideal candidates for curative intent surgery are those with epithelioid MPeM, a low peritoneal cancer index, and a good performance status. Contraindications to curative intent surgery include the sarcomatoid MPeM, distant metastases, extensive nodal metastases, and extensive small bowel serosal or mesentery involvement not amenable to complete cytoreduction. Those with biphasic histology, bicavitary disease, and metastatic lymphadenopathy may be considered for surgery following response to neoadjuvant therapy. CRS involves resection of all peritoneal disease, the extent of which varies case by case. Key aspects involve careful evaluation of all peritoneal surfaces, complete parietal peritonectomy and omentectomy, and evaluating suspicious abdominal lymph node basins. Once maximum cytoreduction is achieved, HIPEC is performed using a platinum-based perfusate. Postoperative protocols are recommended to optimize recovery and mitigate HIPEC-specific complications, namely chemotherapy-mediated nephrotoxicity and bone marrow suppression.
Strategies to Reverse Hypoxic Tumor Microenvironment for Enhanced Sonodynamic Therapy
Authors: Jialun Li, Zhengya Yue, Minglu Tang, Wenxin Wang, Yuan Sun, Tiedong Sun, Chunxia Chen
Journal: Advanced Healthcare Materials (2023)

Sonodynamic therapy (SDT) has emerged as a highly effective modality for the treatment of malignant tumors owing to its powerful penetration ability, noninvasiveness, site-confined irradiation, and excellent therapeutic efficacy. However, the traditional SDT, which relies on oxygen availability, often fails to generate a satisfactory level of reactive oxygen species because of the widespread issue of hypoxia in the tumor microenvironment of solid tumors. To address this challenge, various approaches are developed to alleviate hypoxia and improve the efficiency of SDT. These strategies aim to either increase oxygen supply or prevent hypoxia exacerbation, thereby enhancing the effectiveness of SDT. In view of this, the current review provides an overview of these strategies and their underlying principles, focusing on the circulation of oxygen from consumption to external supply. The detailed research examples conducted using these strategies in combination with SDT are also discussed. Additionally, this review highlights the future prospects and challenges of the hypoxia-alleviated SDT, along with the key considerations for future clinical applications. These considerations include the development of efficient oxygen delivery systems, the accurate methods for hypoxia detection, and the exploration of combination therapies to optimize SDT outcomes.
Hidden Disparities: How Language Influences Patients’ Access to Cancer Care
Authors: Debbie W. Chen, Mousumi Banerjee, Xin He, Lesley Miranda, Maya Watanabe, Christine M. Veenstra, Megan R. Haymart
Journal: Journal of the National Comprehensive Cancer Network (2023)

Background: Patients with limited English proficiency, a vulnerable patient population, remain understudied in the literature addressing cancer disparities. Although it is well documented that language discordance between patients and physicians negatively impacts the quality of patient care, little is known about how patients’ preferred spoken language impacts their access to cancer care. Patients and Methods: Between November 2021 and June 2022, we conducted an audit study of 144 hospitals located across 12 demographically diverse states. Using a standardized script, trained investigators assigned to the roles of English-speaking, Spanish-speaking, and Mandarin-speaking patients called the hospital general information telephone line seeking to access care for 3 cancer types that disproportionately impact Hispanic and Asian populations (colon, lung, and thyroid cancer). Primary outcome was whether the simulated patient caller was provided with the next steps to access cancer care, defined as clinic number or clinic transfer. We used chi-square tests and logistic regression analysis to test for associations between the primary outcome and language type, region type, hospital teaching status, and cancer care requested. We used multivariable logistic regression analysis to determine factors associated with simulated patient callers being provided the next steps. Results: Of the 1,296 calls, 52.9% (n=686) resulted in simulated patient callers being provided next steps to access cancer care. Simulated non–English-speaking (vs English-speaking) patient callers were less likely to be provided with the next steps (Mandarin, 27.5%; Spanish, 37.7%; English, 93.5%; P &lt;.001). Multivariable logistic regression found significant associations of the primary outcome with language spoken (Mandarin: odds ratio [OR], 0.02 [95% CI, 0.01–0.04] and Spanish: OR, 0.04 [95% CI, 0.02–0.06] vs English) and hospital teaching status (nonteaching: OR, 0.43 [95% CI, 0.32–0.56] vs teaching). Conclusions: Linguistic disparities exist in access to cancer care for non–English-speaking patients, emphasizing the need for focused interventions to mitigate systems-level communication barriers.